Company intelligence / Profile preview

Gamida Cell

Jerusalem, Israelgamida-cell.com ↗
Ownership
Public · GMDA
Employees
~100
Development stage
Other
01

Overview

Gamida Cell’s lead product, omidubicel (Omisirge), received FDA approval in April 2023 as an allogeneic umbilical cord blood-derived stem cell therapy to reduce infection risk in patients with blood cancer undergoing bone marrow transplant. Clinical studies showed faster neutrophil engraftment and reduced infections compared to standard cord blood transplants. The company also has a pipeline of NAM-enabled natural killer cell therapies at various stages of development but deprioritized some preclinical work due to financial constraints.

Therapeutic areas
HematologyOncology
Modalities
Allogeneic cell therapy (umbilical cord blood-derived stem cells)Natural killer (NK) cell therapies
Industry
Biotech
02

Drug pipeline

12 assets

omidubicel

Approved

11 more assets in the full pipeline.

03

Partnerships

Collaboration with Dana-Farber Cancer Institute on GDA–601 program targeting multiple myeloma; seeking additional strategic partners or acquirers as of early/mid–2024.

Beyond the preview

Go deeper on Gamida Cell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gamida Cell.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call